Blueprint Medicines Corporation
BPMC
Hisse Senetlerindeki Sıralama
#2358
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Hisse Fiyatı
$129.46
Son senkronizasyon: 2025-07-18
Piyasa Değeri
$8.36B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Blueprint Medicines Corporation (BPMC)
Kategori
Healthcare
Blueprint Medicines Corporation (BPMC) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -41.67%
Blueprint Medicines Corporation şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -41.67%'dir. 2023 yılı sonunda şirketin faaliyet marjı -194.99% idi.
Blueprint Medicines Corporation için 2013 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -41.67% | 0.00% |
| 2024 | -41.67% | -78.63% |
| 2023 | -194.99% | -27.56% |
| 2022 | -269.19% | -25.25% |
| 2021 | -360.10% | -1,045.89% |
| 2020 | 38.07% | -106.91% |
| 2019 | -551.16% | -0.67% |
| 2018 | -554.86% | -20.47% |
| 2017 | -697.64% | 163.22% |
| 2016 | -265.04% | -43.01% |
| 2015 | -465.10% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 38.59% | -100.93% |
US
|
|
| -149.01% | -96.42% |
US
|
|
| 25.57% | -100.61% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.69% |
NL
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.